SCHEMBL7519249

SCHEMBL7519249

C#CCN1CC(=O)NC1=O

nearest known ligand 0.38

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 2/20 0.38
EPHX2 P34913 1/20 0.32
TOP2A P11388 1/20 0.31
TOP2B Q02880 1/20 0.31
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
DDB1 Q16531 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6039701 0.80 CRBN (0.39) CRBNEPHX2TOP2ATOP2BALDH1A1
SCHEMBL8445095 0.75 CRBN (0.35) CRBNEPHX2
SCHEMBL9827070 0.75 CRBN (0.40) CRBNEPHX2TOP2ATOP2BALDH1A1
SCHEMBL8999579 0.74 CRBN (0.46) CRBNEPHX2TOP2ATOP2BALDH1A1
SCHEMBL2411663 0.74 CRBN (0.34) CRBN
SCHEMBL24356068 0.72 LMNA (0.34)
SCHEMBL24356067 0.72 LMNA (0.34)
SCHEMBL561442 0.70
SCHEMBL22114487 0.70
SCHEMBL191785 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1446805-A Method for preparing 1-proparagyl hydantoin KAIDA FINE CHEMICAL INDUSTRY C (CN) 2003-10-08 CN claimed
EP-0560622-B1 A process for producing 1-propargylimidazolidine-2,4-dione SUMITOMO CHEMICAL CO (JP) 2000-08-23 EP claimed
EP-0560581-B1 Process for producing 3-hydroxymethyl-1-propargyl-imidazolidine-2,4-dione SUMITOMO CHEMICAL CO (JP) 2000-06-07 EP claimed
US-5350859-A Process for producing 3-hydroxymethyl-1-propargylimidazolidine-2,4-dione SUMOTOMO CHEMICAL COMPANY, LTD. (JP) 1994-09-27 US claimed
EP-0560622-A2 A process for producing 1-propargylimidazolidine-2,4-dione SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1993-09-15 EP claimed
EP-0560581-A2 Process for producing 3-hydroxymethyl-1-propargyl-imidazolidine-2,4-dione SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1993-09-15 EP claimed
EP-0285270-B1 A METHOD FOR PRODUCING 1-PROPARGYL-2,4-DIOXOIMIDAZOLIDINE SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1992-06-03 EP claimed
EP-0285270-A1 A method for producing 1-propargyl-2,4-dioxoimidazolidine SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-10-05 EP claimed
JP-5255271-A None JP disclosed
CN-222196199-U Impurity filtering device for producing 5, 5-dimethyl hydantoin 河北利仕化学科技有限公司 2024-12-20 CN disclosed
US-20220142157-A1 ARTHROPOD CONTROLLING COMPOSITION FIRMENICH SA (CH) 2022-05-12 US disclosed
CN-114344978-A Filtering device applied to synthesized 5, 5-dimethylhydantoin 河北利仕化学科技有限公司 2022-04-15 CN disclosed
US-20180016275-A1 NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) GALAPAGOS NV (BE) 2018-01-18 US disclosed
CN-104870445-B New dihydro-pyrimidin and isobioquin group and its pharmaceutical composition (GPR84 antagonists) for treating inflammatory disease 加拉帕戈斯股份有限公司 2017-09-15 CN disclosed
US-4827020-A Propargyl amide precursor to 1-propargyl-2,4-dioxoimidazolidine SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1989-05-02 US disclosed
US-4827020-A Propargyl amide precursor to 1-propargyl-2,4-dioxoimidazolidine SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1989-05-02 US disclosed
US-4827020-A Propargyl amide precursor to 1-propargyl-2,4-dioxoimidazolidine SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1989-05-02 US disclosed
EP-0285270-A1 A method for producing 1-propargyl-2,4-dioxoimidazolidine SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-10-05 EP disclosed
EP-0285270-A1 A method for producing 1-propargyl-2,4-dioxoimidazolidine SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-10-05 EP disclosed
EP-0285270-A1 A method for producing 1-propargyl-2,4-dioxoimidazolidine SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 1988-10-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180016275-A1 NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS (GPR84 ANTAGONISTS) GPR84, GPR88, GPR65 CRBN 4060/4885EPHX2 2505/4885TOP2A 4522/4885
US-20220142157-A1 ARTHROPOD CONTROLLING COMPOSITION AGO2, NOP2, FBL CRBN 2092/4885EPHX2 1349/4885TOP2A 3255/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.